Peptides as signaling inhibitors for mammalian MAP kinase cascades

Current Pharmaceutical Design

Volumn 15, Issue 21, 2009, Pages 2471-2480

  Gaestel, Matthias ^a   Kracht, Michael ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

CD domain; DEF domain; DVD; KIM domain; Protein kinase; Protein phosphatase; Protein phosphorylation; Transcription factor

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

APOPTOSIS; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVATION; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; HUMAN; IC 50; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION;

ANIMALS; BINDING SITES; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 69249115278     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682299     Document Type: Review

References (118)

1. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta 2007; 1773: 1376-87.
2. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-12.
3. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-44.
4. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat Rev Mol Cell Biol 2006; 7: 120-30.
5. Gaestel M. Specificity of signaling from MAPKs to MAPKAPKs: Kinases' tango nuevo. Front Biosci 2008; 13: 6050-9.
6. Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal 2003; 15: 455-62.
7. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371: 199-204.
8. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: A further update. Biochem J 2007; 408: 297-315.
9. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
10. Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007; 14: 2214-34.
11. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem.J 2003; 371: 199-204.
12. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J 2000; 351: 95-105.
13. Taylor SS, Radzio-Andzelm E. Protein kinase inhibition: Natural and synthetic variations on a theme. Curr Opin Chem Biol 1997; 1: 219-26
14. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr, et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci USA 1983; 80: 4218-22.
15. Cutler RE, Jr., Stephens, RM, Saracino, MR, Morrison, DK. Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci USA 1998; 95: 9214-9.
16. Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychene A. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol 2007; 27: 31-43.
17. Engel K, Schultz H, Martin F, Kotlyarov A, Plath K, Hahn M, et al. Constitutive activation of mitogen-activated protein kinase-activated protein kinase 2 by mutation of phosphorylation sites and an A-helix motif. J Biol Chem 1995; 270: 27213-21.
18. Zu YL, Ai Y, Huang CK. Characterization of an autoinhibitory domain in human mitogen-activated protein kinase-activated protein kinase 2. J Biol Chem 1995; 270: 202-6.
19. Hayess K, Benndorf R. Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem Pharmacol 1997; 53: 1239-47.
20. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6: 827-37.
21. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002; 12: 14-21.
22. Mooney LM, Whitmarsh AJ. Docking interactions in the c-Jun N-terminal kinase pathway. J Biol Chem 2004; 279: 11843-52.
23. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 1998; 281: 1671-4.
24. Ho DT, Bardwell AJ, Grewal S, Iverson C, Bardwell L. Interacting JNK-docking sites in MKK7 promote binding and activation of JNK MAP kinases. J Biol Chem 2006; 281(19): 13169-79.
25. Takekawa M, Tatebayashi K, Saito H. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell 2005; 18: 295-306.
26. Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal 2003; 15: 455-62.
27. Tanoue T, Maeda R, Adachi M, Nishida E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J 2001; 20: 466-79.
28. Chang CI, Xu BE, Akella R, Cobb MH, Goldsmith EJ. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol.Cell 2002; 9: 1241-9.
29. Weston CR, Lambright DG, Davis RJ. Signal transduction. MAP kinase signaling specificity. Science 2002; 296: 2345-7.
30. Gavin AC, Nebreda AR. A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. Curr Biol 1999; 9: 281-4.
31. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996; 87: 929-39.
32. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15: 2760-70.
33. Sharrocks AD, Yang SH, Galanis A. Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 2000; 25: 448-53.
34. Dunn C, Wiltshire C, MacLaren A, Gillespie DA. Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal 2002; 14: 585-93.
35. May GH, Allen KE, Clark W, Funk M, Gillespie DA. Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo. J Biol Chem 1998; 273: 33429-35.
36. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76: 1025-37.
37. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993; 7: 2135-48.
38. Fukuda M, Gotoh Y, Nishida E. Interaction of MAP kinase with MAP kinase kinase: Its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J 1997; 16: 1901-8.
39. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J 1998; 17: 1740-9.
40. Galanis A, Yang SH, Sharrocks AD. Selective targeting of MAPKs to the ETS domain transcription factor SAP-1. J Biol Chem 2001; 276: 965-73.
41. Smith JA, Poteet-Smith CE, Lannigan DA, Freed TA, Zoltoski AJ, Sturgill TW. Creation of a stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function. J Biol Chem 2000; 275: 31588-93.
42. Tanoue T, Adachi M, Moriguchi T, Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2000; 2: 110-6.
43. Tanoue T, Maeda R, Adachi M, Nishida E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J 2001; 20: 466-79.
44. Yang SH, Galanis A, Sharrocks AD. Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol 1999; 19: 4028-38.
45. Barsyte-Lovejoy D, Galanis A, Clancy A, Sharrocks AD. ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif. Biochem J 2004; 381: 693-9.
46. Tanoue T, Yamamoto T, Maeda R, Nishida E. A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem 2001; 276: 26629-39.
47. Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev 1999; 13: 163-75.
48. Dimitri CA, Dowdle W, MacKeigan JP, Blenis J, Murphy LO. Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr Biol 2005; 15: 1319-24.
49. Mayor F, Jr., Jurado-Pueyo M, Campos PM, Murga C. Interfering with MAP kinase docking interactions: Implications and perspective for the p38 route. Cell Cycle 2007; 6: 528-33.
50. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 2000; 275: 16609-17.
51. Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J 1998; 17: 7337-50.
52. Bardwell L. Mechanisms of MAPK signalling specificity. Biochem Soc Trans 2006; 34: 837-41.
53. Barr RK, Boehm I, Attwood PV, Watt PM, Bogoyevitch MA. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J Biol Chem 2004; 279: 36327-38.
54. Zhu Y, Li H, Long C, Hu L, Xu H, Liu L, et al. Structural insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. Mol Cell 2007; 28: 899-913.
55. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72.
56. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998; 4: 1449-52.
57. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88: 1864-8.
58. Joliot A, Prochiantz A. Transduction peptides: From technology to physiology. Nat Cell Biol 2004; 6: 189-96.
59. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
60. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
61. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladriere L, et al. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochim Biophys Acta 2007; 1768: 2222-34.
62. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003; 19: 91-118
63. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997; 277: 693-6.
64. Yasuda J, Whitmarsh AJ, Cavanagh J, Sharma M, Davis RJ. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol 1999; 19: 7245-54.
65. Kadoya T, Khurana A, Tcherpakov M, Bromberg KD, Didier C, Broday L, et al. JAMP, a Jun N-terminal kinase 1 (JNK1)-associated membrane protein, regulates duration of JNK activity. Mol Cell Biol 2005; 25: 8619-30.
66. Marti A, Luo Z, Cunningham C, Ohta Y, Hartwig J, Stossel TP, et al. Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor-alpha activation of SAPK in melanoma cells. J Biol Chem 1997; 272: 2620-8.
67. Girardin SE, Yaniv M. A direct interaction between JNK1 and CrkII is critical for Rac1-induced JNK activation. EMBO J 2001; 20: 3437-46.
68. Gallagher ED, Xu S, Moomaw C, Slaughter CA, Cobb MH. Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation. J Biol Chem 2002; 277: 45785-92.
69. Xu S, Cobb MH. MEKK1 binds directly to the c-Jun N-terminal kinases/ stress-activated protein kinases. J Biol Chem 1997; 272: 32056-60.
70. Xu Z, Kukekov NV, Greene LA. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J 2003; 22: 252-61.
71. Tapon N, Nagata K, Lamarche N, Hall A. A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways. EMBO J 1998; 17: 1395-404.
72. Kukekov NV, Xu Z, Greene LA. Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs. J Biol Chem 2006; 281: 15517-24.
73. Tsuda M, Langmann C, Harden N, Aigaki T. The RING-finger scaffold protein plenty of SH3s targets TAK1 to control immunity signalling in Drosophila. EMBO Rep 2005; 6: 1082-7.
74. Bonny C, Nicod P, Waeber G. IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem 1998; 273: 1843-6.
75. Waeber G, Delplanque J, Bonny C, Mooser V, Steinmann M, Widmann C, et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 2000; 24: 291-5.
76. Whitmarsh AJ, Davis RJ. Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem Sci 1998; 23: 481-5.
77. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
78. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002; 277: 10987-97.
79. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 2004; 23: 2185-95.
80. Barr RK, Hopkins RM, Watt PM, Bogoyevitch MA. Reverse two-hybrid screening identifies residues of JNK required for interaction with the kinase interaction motif of JNK-interacting protein-1. J Biol Chem 2004; 279: 43178-89.
81. Ho DT, Bardwell AJ, Abdollahi M, Bardwell L. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 2003; 278: 32662-72.
82. Holzberg D, Knight CG, Dittrich-Breiholz O, Schneider H, Dorrie A, Hoffmann E, et al. Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. J Biol Chem 2003; 278: 40213-23.
83. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-6
84. Esneault E, Castagne V, Moser P, Bonny C, Bernaudin M. D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats. Neuroscience 2008; 152: 308-20.
85. Centeno C, Repici M, Chatton JY, Riederer BM, Bonny C, Nicod P, et al. Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell Death Differ 2007; 14: 240-53.
86. Repici M, Centeno C, Tomasi S, Forloni G, Bonny C, Vercelli A, et al. Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation. Neuroscience 2007; 150: 40-9.
87. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: Respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006; 26: 3551-60.
88. Im JY, Lee KW, Kim MH, Lee SH, Ha HY, Cho IH, et al. Repression of phospho-JNK and infarct volume in ischemic brain of JIP1-deficient mice. J Neurosci Res 2003; 74: 326-32.
89. Jaeschke A, Czech MP, Davis RJ. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev 2004; 18: 1976-80.
90. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997; 389: 865-70.
91. Kennedy NJ, Martin G, Ehrhardt AG, Cavanagh-Kyros J, Kuan CY, Rakic P, et al. Requirement of JIP scaffold proteins for NMDA-mediated signal transduction. Genes Dev 2007; 21: 2336-46.
92. Whitmarsh AJ, Kuan CY, Kennedy NJ, Kelkar N, Haydar TF, Mordes JP, et al. Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev 2001; 15: 2421-32.
93. Jaeschke A, Rincon M, Doran B, Reilly J, Neuberg D, Greiner DL, et al. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes. Proc Natl Acad Sci USA 2005; 102: 6931-5.
94. Bonny C, Oberson A, Steinmann M, Schorderet DF, Nicod P, Waeber G. IB1 reduces cytokine-induced apoptosis of insulin-secreting cells. J Biol Chem 2000; 275: 16466-72.
95. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 10: 1128-32.
96. Pirvola U, Xing-Qun L, Virkkala J, Saarma M, Murakata C, Camoratto AM, et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 2000; 20: 43-50.
97. Eshraghi AA, He J, Mou CH, Polak M, Zine A, Bonny C, et al. D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma. Otol Neurotol 2006; 27: 504-11.
98. Eshraghi AA, Wang J, Adil E, He J, Zine A, Bublik M, et al. Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity. Hear Res 2007; 226: 168-77.
99. Wang J, Ruel J, Ladrech S, Bonny C, van de Water TR, Puel JL. Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals. Mol Pharmacol 2007; 71: 654-66.
100. Wang J, Van De Water TR, Bonny C, de Ribaupierre F, Puel JL, Zine A. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003; 23: 8596-607.
101. Beckham JD, Goody RJ, Clarke P, Bonny C, Tyler KL. Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinase. J Virol 2007; 81: 6984-92.
102. Milano G, Morel S, Bonny C, Samaja M, von Segesser LK, Nicod P, Vassalli G. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol 2007; 292: H1828-35.
103. Bardwell AJ, Abdollahi M, Bardwell L. Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity. Biochem J 2003; 370: 1077-85.
104. Kelemen BR, Hsiao K, Goueli SA. Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 2002; 277: 8741-8.
105. Molina DM, Grewal S, Bardwell L. Characterization of an ERK-binding domain in microphthalmia-associated transcription factor and differential inhibition of ERK2-mediated substrate phosphorylation. J Biol Chem 2005; 280: 42051-60.
106. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002; 4: 556-64.
107. Waetzig V, Herdegen T. Context-specific inhibition of JNKs: Overcoming the dilemma of protection and damage. Trends Pharmacol Sci 2005; 26: 455-61.
108. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm.Sci 2006; 27: 311-9.
109. Strickland I, Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006; 65(Suppl 3): Iii75-82.
110. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289: 1550-4.
111. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H, et al. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 2008; 15: 89-93.
112. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007; 39: 741-9.
113. Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, et al. c-Jun/ap-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev 2006; 20: 2306-14.
114. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, et al. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004; 6: 146-53.
115. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, et al. Induction of gadd45beta by NF-kappaB downregulates proapoptotic JNK signalling. Nature 2001; 414: 308-13.
116. Muniyappa H, Das KC. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism. Cell Signal 2008; 20: 675-83.
117. Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation. Arthritis Rheum 2005; 52: 2719-29.
118. Lukas,SM, Kroe RR, Wildeson J, Peet GW, Frego L, Davidson W, et al. Catalysis and function of the p38 alpha.MK2a signaling complex. Biochemistry 2004; 43: 9950-60.